Elicio Therapeutics, INC 8-K filings

Elicio Therapeutics announced the pricing of a registered direct offering expected to raise approximately $15 million in gross proceeds.

Elicio Therapeutics presented clinical data showing complete responses in metastatic pancreatic cancer patients treated with ELI-002 7P followed by checkpoint inhibition.

Elicio Therapeutics announced preliminary clinical observations from its Phase 2 AMPLIFY-7P study, showing complete responses in pancreatic cancer patients treated with ELI-002 7P and subsequent checkpoint inhibition.

Elicio Therapeutics announced Phase 2 AMPLIFY-7P study results for ELI-002 7P in adjuvant pancreatic cancer, which did not meet its primary endpoint in the overall population but showed promise in a specific subgroup.

Elicio Therapeutics announced first quarter 2026 financial results, highlighting progress in its Phase 2 AMPLIFY-7P trial for pancreatic cancer and an extended cash runway.

Elicio Therapeutics, Inc. has established a new at-the-market equity offering program for up to $100 million, replacing a previous $40 million agreement.

Elicio Therapeutics reported full year 2025 financial results and provided positive updates on its Phase 2 AMPLIFY-7P trial for pancreatic cancer, extending its cash runway into Q3 2026.

Elicio Therapeutics reports Q3 2025 financial results, provides corporate updates, and extends its cash runway through Q2 2026, with Phase 2 AMPLIFY-7P data now expected in 1H 2026.

Elicio Therapeutics announced strong immunogenicity data for its ELI-002 7P cancer vaccine, achieving robust mKRAS-specific T cell responses in 99% of evaluable patients in the Phase 2 AMPLIFY-7P trial.

Elicio Therapeutics announced the publication of positive follow-up data from its Phase 1 AMPLIFY-201 study of ELI-002 in Nature Medicine, showing significant survival benefits.

Elicio Therapeutics reported Q2 2025 financial results and announced a positive IDMC recommendation for its ELI-002 7P pancreatic cancer study, extending its cash runway into Q1 2026.

Elicio Therapeutics' ELI-002 7P Phase 2 study for mutant KRAS-driven pancreatic cancer received a positive Independent Data Monitoring Committee recommendation to continue without modifications, indicating preliminary efficacy signals.

Elicio Therapeutics, a clinical-stage biotechnology company, has secured a $10 million senior secured promissory note from GKCC, LLC, an entity controlled by a board member, extending its cash runway into the first quarter of 2026 and beyond a key Phase 2 interim analysis.

Elicio Therapeutics held its 2025 annual meeting where stockholders elected two directors and ratified the appointment of Baker Tilly US, LLP as the company's auditor.

Elicio Therapeutics announced its Q1 2025 financial results, highlighting progress towards the Phase 2 AMPLIFY-7P interim analysis and alignment with the FDA on a Phase 3 study design for ELI-002.

Elicio Therapeutics released its financial results for the year ending December 31, 2024, alongside updates on the company's activities.

Elicio Therapeutics appoints Preetam Shah as Chief Strategy and Financial Officer, effective March 24, 2025.

Elicio Therapeutics converted a $20 million convertible note held by GKCC, LLC into 3,500,573 shares of common stock, increasing the total outstanding shares to 15,861,913.

Elicio Therapeutics, Inc. has announced a $10 million registered direct offering, selling shares and warrants to institutional investors at $7.925 per share.

Elicio Therapeutics highlights its lymph node-targeted immunotherapy approach and provides updates on its clinical programs, particularly ELI-002, in a recent corporate presentation.

Elicio Therapeutics announced it has received supportive feedback from the FDA regarding its Phase 3 registrational strategy for its ELI-002 cancer immunotherapy.

Elicio Therapeutics presented updated Phase 1 results for its ELI-002 cancer vaccine, showing a 16.3-month median recurrence-free survival and a 28.9-month median overall survival in patients with mKRAS-driven cancers.

Elicio Therapeutics has completed enrollment of 135 patients in its Phase 2 AMPLIFY-7P study evaluating ELI-002 for pancreatic cancer, with interim results expected in the first half of 2025.

Elicio Therapeutics successfully held its 2024 annual meeting, electing three directors and approving the ratification of its accounting firm and the issuance of shares related to warrants and a convertible note.

Elicio Therapeutics reported its Q3 2024 financial results, highlighted clinical trial progress, and provided updates on its cancer immunotherapy pipeline.

Elicio Therapeutics announced updated data from its ELI-002 Phase 1 trial showing a correlation between T cell response and disease-free survival in patients with mKRAS-driven solid tumors.

Elicio Therapeutics' annual stockholder meeting was adjourned due to a lack of quorum and will reconvene virtually on November 21, 2024.

Elicio Therapeutics has appointed Robert Connelly, the current CEO and President, as its new Principal Accounting Officer and Principal Financial Officer, effective October 15, 2024.

Elicio Therapeutics' Chief Financial Officer, Brian Piekos, has announced his resignation, effective September 6, 2024, to pursue another opportunity.

Elicio Therapeutics announced encouraging Phase 1 clinical trial results for its ELI-002 7P cancer immunotherapy, along with securing funding to extend operations into the second quarter of 2025.